Skip to main content
. 2020 Oct 3;4(12):1824–1834. doi: 10.1002/hep4.1602

Table 1.

Demographics and baseline characteristics of participants with BA SNL at age 2 years

Variable BASIC (N = 44) PROBE (N = 196) Total (N = 240)
N n (%) or Median (IQR) N n (%) or Median (IQR) N n (%) or Median (IQR)
Demographics
Female 44 28 (63.6%) 196 104 (53.1%) 240 132 (55%)
Race White 43 21 (48.8%) 195 108 (55.4%) 238 129 (54.2%)
Black 43 7 (16.3%) 195 29 (14.9%) 238 36 (15.1%)
Other 43 15 (34.9%) 195 58 (29.7%) 238 73 (30.7%)
Hispanic ethnicity 42 5 (11.9%) 196 48 (24.5%) 238 53 (22.3%)
Age at Kasai (days) 44 61 (40, 76) 196 57 (43, 74) 240 59 (42, 74)
Associated anomalies
Asplenia/polysplenia 37 1 (2.7%) 195 8 (4.1%) 232 9 (3.9%)
Cardiovascular anomaly 37 5 (13.5%) 195 30 (15.4%) 232 35 (15.1%)
Gastrointestinal anomaly 37 8 (21.6%) 195 18 (9.2%) 232 26 (11.2%)
Clinical features
History of GI bleed 44 1 (2.3%) 196 10 (5.1%) 240 11 (4.6%)
History of cholangitis 44 23 (52.3%) 196 81 (41.3%) 240 104 (43.3%)
History of ascites 44 8 (18.2%) 196 34 (17.3%) 240 42 (17.5%)
History of splenomegaly 44 21 (47.7%) 196 117 (59.7%) 240 138 (57.5%)
Weight growth failure 35 4 (11.4%) 178 6 (3.4%) 213 10 (4.7%)
Height growth failure 35 0 (0%) 179 13 (7.3%) 214 13 (6.1%)
Antibiotics 27 11 (40.7%) 194 58 (29.9%) 221 69 (31.2%)
Ursodeoxycholic acid 27 17 (63%) 189 123 (65.1%) 216 140 (64.8%)
Laboratory features
TB (mg/dL) 41 0.5 (0.3, 1.3) 186 0.5 (0.3, 0.9) 227 0.5 (0.3, 0.9)
GGT (U/L) 35 127 (50, 239) 152 134 (43, 332) 187 130 (43, 327)
Platelet count (×103/µL) 38 189 (132, 246) 179 206 (134, 280) 217 205 (134, 271)
APRI 36 1.1 (0.7, 2.7) 176 1.2 (0.6, 2.1) 212 1.2 (0.7, 2.2)
AST (U/L) 40 80 (56, 138) 189 88 (56, 159) 229 84 (56, 154)
ALT (U/L) 40 65 (39, 117) 189 85 (45, 163) 229 83 (42, 155)
Albumin (g/dL) 39 4.1 (3.8, 4.4) 187 4.1 (3.8, 4.4) 226 4.1 (3.8, 4.4)
INR 30 1.0 (1.0, 1.2) 161 1.0 (1.0, 1.1) 191 1.0 (1.0, 1.1)